Larvol Delta - Deucravacitinib-an-Oral-Selective-Tyrosine-Kinase-2-Inhibitor-in-Phase-3-Trials-for-PsA-Achievement-of-Minimal-Disease-Activity-Individual-Components-and-Very-Low-Disease-Activity-Through-Week-52

Sotyktu (deucravacitinib) - BMS

https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570066

Philip Mease, MD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next